Introduction
============

Cyclin-dependent kinase 1 (Cdk1) activity drives many mitotic events, including spindle assembly during mitotic entry and chromosome segregation at anaphase onset ([@bib66]). The ordering of mitotic events therefore requires the ordered and coordinated phosphorylation of many Cdk1 substrates. This ordering is achieved by two mechanisms: substrate specificity conferred by different cyclin subunits whose levels rise and fall in waves during the cell cycle, and a stepwise increase in total Cdk1 activity that reaches a maximum at anaphase onset ([@bib98]; [@bib104]). Although the importance of Cdk1 activity in mitosis has long been recognized, the critical Cdk1 substrates that drive mitotic transitions are poorly defined.

Mitotic onset is regulated in all eukaryotes by an increase in Cdk1 activity caused by the dephosphorylation of Cdk1 on a conserved inhibitory tyrosine (tyrosine 19 in budding yeast; [@bib85]; [@bib69]; [@bib25]; [@bib28]; [@bib35]). The kinase and phosphatase responsible for the modification of this residue are Wee1 and Cdc25, respectively ([@bib31]; [@bib32]). *wee1* mutants in fission yeast shorten G2 by causing premature activation of Cdk1, whereas *cdc25* mutants never accumulate sufficient Cdk1 activity to enter mitosis ([@bib68]; [@bib85], [@bib86]). Wee1 and Cdc25 are the targets of numerous cell cycle checkpoints, all of which delay mitotic entry by activating Wee1 or inhibiting Cdc25 ([@bib44]).

Budding yeast Wee1 (Swe1) and Cdc25 (Mih1) are targets of a morphogenesis checkpoint that has been shown to delay mitotic onset in response to either defects in the actin cytoskeleton, small cell size, or the extent of membrane growth ([@bib54]; [@bib61]; [@bib34]; [@bib62]; [@bib2]). Although multiple signals may activate this checkpoint, all of its effects depend on phosphorylation and inhibition of Cdk1 (encoded by the yeast *CDC28* gene; [@bib54]). Most work has focused on a role for this checkpoint in blocking mitotic entry; however, there is evidence that the checkpoint also causes delays during mitosis ([@bib11]; [@bib3]; [@bib94]; [@bib102]; [@bib16]). The downstream targets of Cdk1 whose reduced phosphorylation is responsible for checkpoint arrest have not been identified.

Cdk1 activity is required for anaphase onset. Mutants in Cdk1 delay in metaphase, and mutation of two mitotic cyclins, *CLB1* and *CLB2*, causes a permanent arrest before anaphase initiation ([@bib83]; [@bib79]), suggesting that only a low level of Cdk1 activity is needed for cells to reach metaphase. Cdk1 regulation of anaphase onset is thought to occur by the phosphorylation and activation of the anaphase-promoting complex or cyclosome (APC; [@bib26]; [@bib46]; [@bib52]; [@bib74]; [@bib92]; [@bib82]; [@bib47]).

The APC is a multi-subunit E3 ubiquitin ligase ([@bib46]; [@bib100]; [@bib75]) that targets Securin (Pds1 in budding yeast) for degradation, relieving its repression of Separase (Esp1), the protease that triggers sister chromatid separation ([@bib18]; [@bib27]; [@bib17]). In mitotic cell cycles two sub-stoichiometric activators, Cdc20 and Cdh1, activate the APC. Cdc20 activates the APC in mitosis and catalyzes Pds1 and mitotic cyclin destruction ([@bib106]; [@bib116]). Cdh1 is activated late in mitosis, completes the destruction of APC substrates, and remains active through G1 ([@bib89]; [@bib106]; [@bib118]). Cdk1 activates APC^Cdc20^ and inhibits APC^Cdh1^ ([@bib118]; [@bib40]; [@bib48]; [@bib82]). This opposing regulation by Cdk1 allows the transfer of ubiquitination activity from Cdc20 to Cdh1 as cells transition from mitosis to G1 ([@bib22]).

Cdk1 activates vertebrate APC in vitro, and mutation of 12 Cdk1 sites on the TPR subunits Cdc16, Cdc23, and Cdc27 in budding yeast (hereafter called *apc-12A*) reduces APC phosphorylation in vivo and in vitro, and APC activity in vivo ([@bib52]; [@bib92]; [@bib48]; [@bib82]; [@bib29]; [@bib47]). The *apc-12A* mutations cause a delay in mitosis and weaken the APC--Cdc20 interaction, but have no effect on APC^Cdh1^ activity ([@bib82]).

Recent work has begun to characterize the phosphatases that dephosphorylate Cdk1 substrates, and how their inactivation promotes mitosis and their activation assists entry into G1 ([@bib97]; [@bib104]; [@bib64]). In budding yeast the phosphatase Cdc14 is released from the nucleolus in early anaphase and dephosphorylates many Cdk1 substrates ([@bib107]; [@bib40]; [@bib6]). Although the *CDC14* gene is highly conserved, the reversal of mitotic phosphorylation in other eukaryotes depends primarily on other phosphatases such as protein phosphatase 1 (PP1) and protein phosphatase 2A (PP2A; [@bib112]). PP2A opposes Cdk1 phosphorylation of Wee1 and Cdc25, and is also believed to be the major phosphatase that antagonizes Cdk1 during mitosis ([@bib49]; [@bib15]; [@bib13]; [@bib65]; [@bib36]; [@bib111]; [@bib51]).

Similar to *swe1Δ*, deletion of *CDC55*, a B-regulatory subunit of PP2A, allows bypass of the morphogenesis checkpoint ([@bib16]). *cdc55Δ* cells also bypass the spindle checkpoint, which monitors bipolar attachment of chromosomes to the mitotic spindle ([@bib63]; [@bib109]). These phenotypes suggest that in *cdc55Δ* cells a mitotic Cdk1 substrate may be inappropriately activated, resulting in a checkpoint defect.

Previously identified mitotic functions of PP2A^Cdc55^ cannot explain its requirement in preventing anaphase onset during morphogenesis and spindle checkpoint activation. *cdc55Δ* cells exhibit elevated tyrosine 19 phosphorylation on Cdk1 due to misregulation of Swe1 and/or Mih1 ([@bib63]; [@bib109]; [@bib114]; [@bib72]). Increased phosphotyrosine, however, would strengthen, not bypass, the morphogenesis checkpoint, and changes in inhibitory phosphorylation on Cdk1 do not cause spindle checkpoint defects ([@bib83]). PP2A^Cdc55^ also inhibits Cdc14 release from the nucleolus after anaphase onset, and early release of Cdc14 has been proposed to cause the *cdc55Δ* spindle checkpoint defect ([@bib110]; [@bib115]). This model, however, does not explain *cdc55Δ* bypass of the morphogenesis checkpoint, as deleting *CDC55* causes checkpoint bypass even in the absence of Cdc14 ([@bib16]).

Because Cdk1 activity is needed to initiate the metaphase-to-anaphase transition we wondered if Swe1 inhibition of Cdk1 regulates anaphase onset. Here we show that deletion of *SWE1* and *MIH1* alters the length of mitosis, and inducing high levels of inhibitory phosphorylation on Cdk1 causes a prolonged metaphase arrest, suggesting that although the morphogenesis checkpoint delays mitotic entry its primary arrest point is in metaphase. During this arrest the APC is dephosphorylated, and the APC^Cdc20^ is inhibited both in vivo and in vitro. We also show that PP2A^Cdc55^ counteracts Cdk1-dependent phosphorylation of the APC, and misregulation of APC phosphorylation in *cdc55Δ* cells partly explains their checkpoint defects. This data confirms that the APC is a target of a Wee1-dependent checkpoint, and suggests the model that dephosphorylation of the inhibitory tyrosine on Cdk1 during mitosis is needed to accumulate sufficient Cdk1 activity to trigger anaphase.

Results
=======

Swe1 inhibition of Cdk1 occurs during mitosis
---------------------------------------------

Swe1 has been shown to function in G2, before spindle assembly ([@bib34]; [@bib19], [@bib20]; [@bib79]), but we wanted to determine whether tyrosine 19 phosphorylation regulates Cdk1 during mitosis. We monitored the sum of Swe1 and Mih1 activity by blotting for tyrosine 19 phosphorylation on Cdk1 during a synchronous cell cycle. Peak Cdk1-Y19 phosphorylation correlates with peak levels of Securin (Pds1), Shugoshin (Sgo1), and the mitotic cyclin Clb3; and just before the peak of the mitotic cyclin Clb2 ([Fig. 1 A](#fig1){ref-type="fig"}; see [Fig. S1 A](http://www.jcb.org/cgi/content/full/jcb.201212038/DC1){#supp1} for evidence that Sgo1 degradation depends on the APC; [@bib41]). This peak occurs after spindle assembly (Fig. S1, B and C) and begins to drop only as the APC becomes active, suggesting that Swe1 may inhibit Cdk1 until the metaphase-to-anaphase transition. Additionally, the peak levels of Clb2 and Pds1 occur 5 min earlier in *swe1Δ* relative to wild-type cells, and 5--10 min later in *mih1Δ* cells despite having no effect on bud emergence, suggesting that both Swe1 and Mih1 regulate anaphase onset (Fig. S1 B).

![**Swe1 and Mih1 regulate anaphase onset.** (A) Swe1 is present and active during mitosis. Wild-type (ADR4009) cells were arrested in G1 with 100 ng/ml α-factor, and released into the cell cycle (t = 0). 800 ng/ml α-factor was re-added at t = 55 min to arrest cells in the following G1. Samples for immunoblotting were taken at the indicated time points. (B--D) Swe1 inhibits and Mih1 promotes anaphase onset. Wild-type (ADR4009), *swe1*Δ (ADR4015), and *mih1*Δ (ADR4012) cells were arrested in G1 with 25 ng/ml α-factor, washed, and resuspended in synthetic media. After 25 min cells were placed on synthetic media agar pads and imaged using fluorescence microscopy. All strains were imaged on the same day and imaged on three separate occasions. Spindle length was determined by measuring the distance between spindle pole bodies tagged with Spc42-eGFP. Representative spindle measurements for cells progressing through mitosis are shown in B. Spc42-eGFP images for the spindles graphed in B are shown in C. (D) The length of metaphase (average ± SEM) was calculated for wild-type, *swe1*Δ, and *mih1*Δ cells by measuring the time spent between spindle formation and anaphase onset. Each pairwise comparison is significantly different (ANOVA, P \< 0.0001, Tukey's HSD = 2.1878 for P \< 0.05). (E) Swe1 and Mih1 do not regulate spindle formation. The spindle lengths (average ± SEM) every minute after spindle formation were calculated from the wild-type, *swe1*Δ, and *mih1*Δ time courses in B.](JCB_201212038R_Fig1){#fig1}

Swe1 and Mih1 regulate anaphase onset in unperturbed mitosis
------------------------------------------------------------

To determine if Cdk1-Y19 phosphorylation regulates anaphase onset we monitored the length of time that wild-type, *swe1Δ*, and *mih1Δ* cells spend in metaphase---defined here as the time between formation of a short metaphase spindle and rapid spindle elongation at anaphase---by imaging cells with Spc42-GFP--labeled spindle poles ([Fig. 1, B and C](#fig1){ref-type="fig"}). The average length of metaphase in wild-type (22.42 min) is significantly longer than in *swe1Δ* (18.85 min), and shorter than in *mih1Δ* (24.93 min), suggesting that tyrosine phosphorylation on Cdk1 regulates the timing of anaphase onset ([Fig. 1 D](#fig1){ref-type="fig"}).

Consistent with prior reports ([@bib34]; [@bib79]; [@bib71]), we observe that *swe1Δ* cells also form metaphase spindles significantly earlier than wild-type cells after being released from G1 (48.55 min compared with 54.79 min; Fig. S1 D), showing that Swe1 regulates both mitotic entry and anaphase onset. The length of the metaphase spindle and its rate of assembly are unchanged in *swe1Δ* and *mih1Δ* cells, suggesting that inhibitory phosphorylation on Cdk1 does not affect the mechanics or kinetics of bipolar spindle formation ([Fig. 1 E](#fig1){ref-type="fig"} and [Fig. 2 C](#fig2){ref-type="fig"}).

![**The morphogenesis checkpoint regulates anaphase onset.** (A and B) Morphogenesis checkpoint activation delays anaphase onset. Wild-type (ADR4009), *swe1*Δ (ADR4015), and *cdk1-Y19F* (ADR4313) cells were arrested in G1 with 25 ng/ml α-factor, washed, and resuspended in synthetic media. After 25 min cells were plated on synthetic media agar pads containing 2.5 µM latA or DMSO and imaged as in [Fig. 1 B](#fig1){ref-type="fig"}. (A) Spindle measurements for single representative wild-type and *swe1*Δ cells progressing through mitosis. (B) The length of time spent from spindle formation to anaphase onset was calculated for wild-type, *swe1*Δ, and *cdk1-Y19F* cells. Cells that spent \>60 min with short spindles are characterized as "metaphase arrested," whereas cells that spent \<60 min with short spindles are characterized as "unarrested." Wild-type and *swe1*Δ ± latA were imaged on three separate occasions and *cdk1-Y19F* ± latA were imaged on two separate occasions. The graph combines all data from all experiments. (C) Morphogenesis checkpoint activation does not perturb mitotic spindle formation. The spindle length (average ± SEM) every minute after spindle formation was calculated for all wild-type, *swe1*Δ, and *cdk1-Y19F* cells from B. (D) Morphogenesis checkpoint activation does not prevent spindle bipolarity. *NDC80-eGFP* (ADR5026) cells were grown and imaged as in A. The distance between separated Ndc80-eGFP foci was measured in cells entering anaphase (DMSO) and 150 min after α-factor wash-out (latA, inset). Gray lines are individual cell measurements; yellow and brown lines are average (±SEM) measurements.](JCB_201212038R_Fig2){#fig2}

We also examined anaphase spindle elongation in *swe1Δ* and *mih1Δ* cells. Other than a small but significant increase in the rate of slow anaphase movement in *mih1Δ* cells, we see little difference between *swe1Δ*, *mih1Δ*, and wild-type cells ([Fig. S2](http://www.jcb.org/cgi/content/full/jcb.201212038/DC1){#supp2}).

The morphogenesis checkpoint arrests cells at metaphase
-------------------------------------------------------

Inhibitory phosphorylation on Cdk1 is the target of the morphogenesis checkpoint ([@bib54]; [@bib34]), so we investigated if this checkpoint arrests cells in metaphase. Past work has shown that this checkpoint slows the cell cycle before nuclear division ([@bib54]; [@bib61]), but whether the checkpoint functions before and/or after spindle assembly has been debated ([@bib56]; [@bib34]; [@bib19], [@bib20]; [@bib16]).

Using *SPC42-eGFP* we observed that checkpoint activation with the actin-depolymerizing drug latrunculin A (latA) causes more than 95% of wild-type cells to arrest for greater than 60 min with short metaphase spindles ([Fig. 2, A and B](#fig2){ref-type="fig"}). *swe1Δ* and *cdk1-Y19F* cells completely bypass this arrest ([Fig. 2 B](#fig2){ref-type="fig"}).

As in unperturbed *swe1Δ* and *mih1Δ* cells, we see no defect in the assembly of a bipolar spindle when the morphogenesis checkpoint is activated ([Fig. 1 E](#fig1){ref-type="fig"} and [Fig. 2 C](#fig2){ref-type="fig"}). To confirm that these cells are indeed arresting at metaphase we monitored kinetochore biorientation using a fluorescently tagged component of the kinetochore, *NDC80-GFP*. Ndc80-GFP foci are on average 1.13 ± 0.08 µm apart in control cells before anaphase onset, and rapidly separate at the metaphase-to-anaphase transition ([Fig. 2 D](#fig2){ref-type="fig"}). Ndc80-GFP foci are similarly separated in cells that are arrested by the morphogenesis checkpoint ([Fig. 2 D](#fig2){ref-type="fig"}, inset).

During morphogenesis checkpoint arrest Swe1 protein is stabilized and phosphorylated, tyrosine phosphorylation accumulates on Cdk1, and APC substrates are stabilized ([Fig. 3 A](#fig3){ref-type="fig"}). *swe1Δ* and *cdk1-Y19F* cells treated with latA accumulate and degrade APC substrates with similar kinetics as untreated wild-type, *swe1Δ*, and *cdk1-Y19F* cells ([Fig. 3 A](#fig3){ref-type="fig"} and [Fig. S3 A](http://www.jcb.org/cgi/content/full/jcb.201212038/DC1){#supp3}). As in our measurements of live cells ([Fig. 2, A and B](#fig2){ref-type="fig"}), wild-type cells treated with latA delay anaphase by at least 60 min, while the kinetics of anaphase onset is identical in treated or untreated *swe1Δ* cells ([Fig. 3 B](#fig3){ref-type="fig"}). Deletion of *CDC55* has also been reported to bypass the morphogenesis checkpoint ([@bib16]). Here, *cdc55Δ* cells treated with latA also initiate anaphase with similar kinetics as untreated cells, but in these cells inhibitory phosphorylation on Cdk1 persists and APC substrates are degraded slowly ([Fig. 3, A and B](#fig3){ref-type="fig"}). The elevated levels of tyrosine-phosphorylated Cdk1 and Swe1 in *cdc55Δ* cells has been reported previously ([@bib63]; [@bib72]; [@bib36]) and is due to PP2A^Cdc55^ activation of Mih1 and inhibition of Swe1. The phenotype of *cdc55Δ* will be discussed in greater detail below.

![**The morphogenesis checkpoint stabilizes APC substrates.** (A and B) Activation of the morphogenesis checkpoint stabilizes APC substrates. Wild-type (ADR4009), *swe1*Δ (ADR4015), and *cdc55*Δ (ADR4738) cells were arrested in G1 with 100 ng/ml α-factor, washed, and released from the arrest (t = 0). Cells were treated with 2.5 µM latA or DMSO at t = 25 and 800 ng/ml α-factor was re-added at t = 65 to arrest cells in the following G1. Samples for immunoblotting (A) and fluorescence microscopy (B) were taken at the indicated time points. Anaphase onset was determined by scoring the distance between Spc42-eGFP--labeled SPBs in fixed cells. At least 200 cells were scored for each time point. (C) LatA-activated Swe1 does not preferentially phosphorylate a particular Cdk1--cyclin complex. Wild-type (ADR4006) cells were arrested with 100 ng/ml α-factor, 10 µg/ml nocodazole, or 2.5 µM latA. Cells were harvested for immunoblotting (left), or, for the latA-arrested cells, immunoprecipitation. Cdk1--Clb2, --Clb3 or --Clb5 complexes were immunoprecipitated, normalized for Cdk1 levels, and blotted for Cdk1 and Cdk1--P-tyr to compare the relative stoichiometry of tyrosine-phosphorylated Cdk1. Two independent experiments are shown, one that compares Clb3 and Clb5 immunoprecipitates (left) and one that compares Clb2 and Clb5 immunoprecipitates.](JCB_201212038R_Fig3){#fig3}

We wondered whether morphogenesis checkpoint activation causes preferential phosphorylation of specific Cdk1--Clb complexes. We therefore immunoprecipitated different Clb--Cdk1 complexes during a morphogenesis checkpoint arrest and found that the ratio of tyrosine-phosphorylated Cdk1 to total Cdk1 is nearly identical for each Clb complex. Consistent with a previous report, this shows that in vivo Swe1 has no obvious preference for a specific Cdk1--Clb complex during checkpoint arrest ([Fig. 3 C](#fig3){ref-type="fig"}; [@bib42]).

Swe1 phosphorylation of Cdk1 inhibits the APC in vivo
-----------------------------------------------------

The stabilization of APC substrates during morphogenesis checkpoint arrest suggests that the APC may be a target of this checkpoint. To avoid the expense and variability of latA, and evaluate the effects of inhibitory phosphorylation on Cdk1 in additional conditions, we tested if overexpression of Swe1 might serve as a valid model for checkpoint arrest ([@bib5]; [@bib19]). After overexpression of Swe1 (*GAL-SWE1*), inhibitory phosphorylation on Cdk1 accumulates to levels nearly identical to that seen during a latA arrest despite an enormous difference in the levels of Swe1 protein ([Fig. 4 A](#fig4){ref-type="fig"}). Because the effects of latA depend fully on tyrosine 19 on Cdk1 (Fig. S3 A), we further characterized the effects of Swe1 overexpression.

![**Overexpression of Swe1 blocks cells in metaphase.** (A) Swe1 overexpression and latA induce similar levels of tyrosine phosphorylation on Cdk1. Wild-type (ADR4009) cells were treated with latA and *GAL-SWE1* (ADR4289) cells were grown in YEP + 2% raffinose (Raff) and induced by addition of 2% galactose (Gal). Cells were harvested and immunoblotted for Swe1, Cdk1, and Cdk1-P-tyr. (B and C) Overexpression of Swe1 in mitosis stabilizes APC substrates and arrests cells with 2N DNA content. Wild-type (ADR2617), *GAL-SWE1* (ADR3871), and *GAL-SWE1 cdk1-Y19F* (ADR4228) cells were grown in YEP + 2% raffinose, arrested with 10 µg/ml nocodazole, and induced with 2% galactose (t = 0) for 1 h. Nocodazole was washed out, and cells released into YEP + 2% galactose. 25 ng/ml α-factor was added (t = 150) to arrest cells in the following G1. Samples were taken for immunoblotting (A) and flow cytometry (B) at the indicated time points. (D) Swe1 inhibits Clb-associated kinase activity. Cells were grown as in A, and Cdk1--Clb2, --Clb3 or --Clb5 complexes were immunoprecipitated with anti-Clb antibodies and their histone H1 kinase activity was measured to assess Cdk1 inhibition. (E) Overexpression of Swe1 impairs sister chromatid separation. Wild-type (ADR1393) and *GAL-SWE1* (ADR1395) strains were grown as in A, except 1 mM CuSO~4~ was added at t = −30 to induce expression of GFP-lacI, and the separation of sister *lacO* arrays at *TRP1* (∼12 kb from *CENIV)* was visualized by fluorescence microscopy. The graphs in D and E are representative of one of three repeats. (F) Overexpressed Swe1 does not preferentially phosphorylate a particular Cdk1--cyclin complex. *GAL-SWE1* cells (ADR3871) were grown as in A, and Cdk1--Clb2, --Clb3, or --Clb5 complexes were immunoprecipitated at the indicated time points and analyzed by immunoblotting with anti-Cdk1 and anti--Cdk1-P-tyr antibodies. (G) Overexpression of Swe1 in anaphase restabilizes APC^Cdc20^ substrates. *cdc15-2* (ADR4252) and *cdc15-2 GAL-SWE1* (ADR4245) cells were grown in YEP + 2% raffinose and arrested in anaphase by temperature shift to 35°C, followed by induction with 2% galactose (t = 0). Parallel cultures were arrested in 10 µg/ml nocodazole (noc) at 25°C to illustrate peak levels of APC substrates. Cdk1 was used as a loading control for three independent membranes loaded with identical samples.](JCB_201212038R_Fig4){#fig4}

To examine the effect of Swe1 overexpression during mitosis we induced *GAL-SWE1* during a nocodazole arrest, washed away the nocodazole allowing cell cycle progression, and monitored cell cycle progression by immunoblot. Control cells release from the nocodazole arrest and reenter G1 after 2 h ([Fig. 4, B and C](#fig4){ref-type="fig"}). Similar to latA treatment ([Fig. 3 A](#fig3){ref-type="fig"}), when Swe1 is induced to high levels, inhibitory phosphorylation accumulates on Cdk1, the APC substrates Clb2, Clb3, Clb5, Pds1, and Sgo1 remain stable, and DNA content remains at 2N. These cells rebuild short metaphase spindles at a slightly slower rate than wild-type cells ([Fig. S4 A](http://www.jcb.org/cgi/content/full/jcb.201212038/DC1){#supp4}), but these spindles do not elongate and sister chromatid separation is blocked ([Fig. 4 E](#fig4){ref-type="fig"}), indicating that these cells remain arrested in metaphase. This arrest is not caused by activation of the spindle or DNA damage checkpoints as *mad2Δ* and *mec1Δ* cells, which are defective in these checkpoints, arrest in mitosis when Swe1 is overexpressed (Fig. S4, B and C). *cdk1-Y19F* cells overexpressing Swe1 release normally from the mitotic arrest and degrade APC substrates as they enter G1 ([Fig. 4, B and C](#fig4){ref-type="fig"}). Additionally, overexpression of a kinase-dead version of Swe1, *swe1-N584A*, also does not cause mitotic arrest, ruling out the possibility that high levels of Swe1, whose degradation depends on the APC ([@bib103]), competitively inhibits the APC (Fig. S4 D).

As expected, Cdk1 activity falls as tyrosine phosphorylation accumulates on Cdk1. After 60 min of Swe1 induction, the Clb2-, Clb3- and Clb5-associated histone H1 kinase activity falls to 60--80% of its starting activity ([Fig. 4 D](#fig4){ref-type="fig"}, green lines), compared with wild-type cells whose Clb-associated activity falls to undetectable levels as they reenter G1 (yellow lines). When these precipitates are probed for tyrosine-phosphorylated Cdk1 all three cyclins are associated with phosphorylated Cdk1, revealing that as during latA treatment ([Fig. 3 C](#fig3){ref-type="fig"}), Swe1 does not preferentially target a particular Cdk1--Clb complex ([Fig. 4 F](#fig4){ref-type="fig"}).

Expression of Swe1 during anaphase, after the APC^Cdc20^ has been activated, is also sufficient to turn off the APC^Cdc20^. When Swe1 is overexpressed in anaphase-arrested *cdc15-2* cells, Clb5, Pds1, and Sgo1 are restabilized, accumulating to levels as high as seen during a nocodazole arrest ([Fig. 4 G](#fig4){ref-type="fig"}).

Swe1 phosphorylation of Cdk1 inhibits APC phosphorylation and activity
----------------------------------------------------------------------

Cdk1-dependent phosphorylation of the APC activates the APC^Cdc20^ in vivo ([@bib82]), so we investigated if high levels of Swe1 reduce APC phosphorylation. To observe the phosphorylation status of the entire APC we monitored phosphorylation of purified APC after metabolic labeling of cells with inorganic ^32^P-labeled orthophosphate. Induction of high levels of Swe1 causes a quantitative loss of phosphorylation on five APC subunits: Apc1, Cdc16, Cdc27, Cdc23, and Apc9 ([Fig. 5 A](#fig5){ref-type="fig"}; [Fig. S5 A](http://www.jcb.org/cgi/content/full/jcb.201212038/DC1){#supp5}). The rapid dephosphorylation of Cdc27 is also observed by immunoblotting ([Fig. 4 B](#fig4){ref-type="fig"}).

![**Overexpression of Swe1 in mitosis inhibits APC phosphorylation in vivo and APC^Cdc20^ activity in vitro.** (A) Wild-type (ADR22), *CDC16-TAP* (ADR3877), and *GAL-SWE1 CDC16-TAP* (ADR3858) cells were grown in YEP + 2% raffinose, arrested in mitosis with 10 µg/ml nocodazole, and induced with 2% galactose for 90 min. Cells were then washed in medium lacking phosphate, and grown for 45 min in the presence of \[^32^P\]orthophosphate. The APC was purified, run on a polyacrylamide gel, and exposed to a phosphorimager screen or immunoblotted. (B) Overexpression of Swe1 inhibits ubiquitination of Pds1 in vitro. *swe1Δ CDC16-TAP* (ADR3877) and *GAL-SWE1 CDC16-TAP* (ADR3859) cells were grown in YEP + 2% raffinose, arrested in mitosis with 30 µg/ml benomyl, and induced with 2% galactose. The APC was purified and its activity assayed in an in vitro ubiquitination assay. Reactions were run on a polyacrylamide gel and exposed to a phosphorimager screen. The average activity (±SEM) of three independent experiments is plotted below a representative assay. APC^Cdc20^ activity was quantified from assays containing methylated ubiquitin (Ub) and APC^Cdh1^ activity was quantified from assays containing wild-type ubiquitin. (C) Cdk1--Clb2 kinase treatment reactivates Swe1-inhibited APC. APC was purified from *swe1Δ CDC16-TAP* and *GAL-SWE1 CDC16-TAP* cells as described in B. The APC was incubated with purified Cdk1--Clb2 complexes ± ATP before cleavage from IgG-coupled magnetic beads. The activity of the purified APC was then measured as in B. Quantification of a representative assay is shown below. Parallel samples were treated with γ-\[^32^P\]ATP to confirm efficient phosphorylation ([Fig. S5 H](http://www.jcb.org/cgi/content/full/jcb.201212038/DC1){#supp6}). (D) *CDC16-TAP* (ADR3089), *cdc16-6A-TAP* (ADR3822), and *cdc16-6A-TAP cdc27-5A* (ADR3891) cells were arrested in mitosis with 30 µg/ml benomyl. Purified APC ([Fig. S5 I](http://www.jcb.org/cgi/content/full/jcb.201212038/DC1){#supp7}) was phosphorylated by purified Cdk1--Clb2 complexes as in C and its activity measured. Quantification of a representative assay is shown below. Parallel samples were treated with γ-\[^32^P\]ATP to confirm efficient phosphorylation ([Fig. S5 J](http://www.jcb.org/cgi/content/full/jcb.201212038/DC1){#supp8}). The experiments shown in B, C, and D are representative of one of two repeats. (E) *mih1Δ* lowers the maximum permissive temperature of *cdc20*-3. Eightfold serial dilutions of wild-type (ADR22), *mih1Δ* (ADR3178), *swe1Δ* (ADR3170), *cdc20-3* (ADR3161), *mih1Δ cdc20-3* (ADR3149), *swe1Δ cdc20-3* (ADR3155), and *swe1Δ mih1Δ cdc20-3* (ADR3141) cells were spotted onto YEPD plates and grown at the indicated temperatures.](JCB_201212038_Fig5){#fig5}

We directly assayed APC activity from cells overexpressing Swe1 to test if Swe1-dependent inhibition of APC phosphorylation lowers APC^Cdc20^ activity in vitro. APC purified from cells overexpressing Swe1 has reduced APC^Cdc20^ activity against Pds1 ([Fig. 5 B](#fig5){ref-type="fig"}; Fig. S5, B and C) and Clb5 (Fig. S5 D). Each ubiquitinated species is reduced approximately twofold ([Fig. 5 B](#fig5){ref-type="fig"}), with little difference between individual ubiquitinated species (Fig. S5 E).

When the Swe1-inhibited APC is assayed using the activator Cdh1, there is no change in APC^Cdh1^ activity relative to control APC ([Fig. 5 B](#fig5){ref-type="fig"}; Fig. S5 C). This is consistent with past data that suggest APC^Cdh1^ activity is unaffected by the phosphorylation of core APC subunits ([@bib118]; [@bib82]).

If the loss of APC^Cdc20^ activity is due solely to a reduction in Cdk1-dependent phosphorylation of the APC, we reasoned we could reactivate the APC by phosphorylating it in vitro with purified Cdk1--Clb2 complexes (Fig. S5 F). After phosphorylation by Cdk1--Clb2, the Swe1-inhibited APC is phosphorylated primarily on Cdc16 and Cdc27 (Fig. S5, G and H), and this phosphorylation greatly increases APC^Cdc20^ activity ([Fig. 5 C](#fig5){ref-type="fig"}, +ATP). Mutating Cdk1 sites on Cdc16 (*cdc16-6A*) partially blocks reactivation, whereas mutating sites on both Cdc16 and Cdc27 (*cdc16-6A cdc27-5A)* further prevents this reactivation ([Fig. 5 D](#fig5){ref-type="fig"}).

Reinforcing this in vitro data we see a strong genetic interaction between *mih1Δ* and mutants in the APC activators, *cdh1Δ* and *cdc20-3*. *mih1Δ* and *cdh1Δ* are synthetically lethal (Fig. S5 K), and *mih1Δ* and *cdc20-3* are synthetically sick, with a lower maximum permissive temperature ([Fig. 5 E](#fig5){ref-type="fig"}). Both of these interactions are fully rescued by *swe1Δ*.

PP2A^Cdc55^ regulates APC phosphorylation and activity
------------------------------------------------------

PP2A is a heterotrimeric complex composed of a catalytic subunit, an A-regulatory or scaffolding subunit, and one of two B-regulatory subunits (*CDC55* or *RTS1*; [@bib37]; [@bib57]; [@bib95]; [@bib93]; [@bib112]). The B-regulatory subunits provide specificity to the two forms of the phosphatase, PP2A^Cdc55^ and PP2A^Rts1^. Cells deleted for *CDC55* also bypass the morphogenesis checkpoint ([@bib16]). As mentioned above, *cdc55Δ* and *swe1Δ* cells initiate anaphase and reenter S phase with similar kinetics after treatment with latA ([Fig. 3 B](#fig3){ref-type="fig"}; Fig. S3 B). However, in *cdc55Δ* cells Swe1 is stabilized, tyrosine phosphorylation on Cdk1 remains high, and APC substrates, including Pds1, are degraded very slowly ([Fig. 3 A](#fig3){ref-type="fig"}). The marked difference between *swe1Δ* and *cdc55Δ* suggests that *cdc55Δ* may bypass the checkpoint through a different mechanism than *swe1Δ*, and we hypothesized its checkpoint defect may be caused by counteracting Cdk1 activation of the APC.

We therefore examined if APC phosphorylation is altered in *cdc55Δ* cells using metabolic labeling. Deletion of *CDC55* causes a dramatic increase in the phosphorylation of Cdc16, Cdc27, and Cdc23, as well as reproducible changes in the phosphorylation of Apc1, Apc4, and Apc5 ([Fig. 6 A](#fig6){ref-type="fig"}). Purified PP2A^Cdc55^ can also dephosphorylate purified APC that has been phosphorylated in vitro by Cdk1--Clb2 ([Fig. 6 B](#fig6){ref-type="fig"}; Fig. S5 L). The dephosphorylation of Apc1, Cdc16, Cdc27, and Apc9 occur at similar rates (blue lines), while Cdc23 is not dephosphorylated. Cdc23 is also poorly phosphorylated by Cdk1--Clb2, suggesting that it may be inaccessible in these in vitro reactions. The dephosphorylation of the APC in vitro by PP2A^Cdc55^ is blocked by the addition of 2 µM okadaic acid, confirming that it is performed by a PP2A complex and not a contaminating phosphatase (Fig. S5 M).

![**PP2A^Cdc55^ regulates APC phosphorylation and activity in vivo.** (A) The APC is hyper-phosphorylated in vivo in *cdc55Δ* cells. *cdc15-2* (ADR1168), *cdc15-2 CDC16-TAP* (ADR5137), and *cdc15-2 cdc55Δ CDC16-TAP* (ADR4060) cells were arrested in G1 with 100 ng/ml α-factor, washed, and released at 37°C. After 2.5 h cells were washed in medium lacking phosphate, and grown for 45 min in the presence of \[^32^P\]orthophosphate at 37°C. The APC was purified, run on a polyacrylamide gel, and exposed to a phosphorimager screen or immunoblotted. (B) PP2A^Cdc55^ dephosphorylates the APC in vitro. The APC was purified from *CDC16-TAP* (ADR3089) cells and phosphorylated with purified Cdk1/Clb2 and γ-\[^32^P\]ATP while immobilized on IgG-coupled magnetic beads. The beads were washed and then incubated for the indicated times at room temperature with no addition (yellow lines), TAP-purified PP2A^Cdc55^ (blue lines), or lambda phosphatase (red lines). The three reactions share a t = 0 sample that was taken before additions. The dephosphorylation of individual APC subunits was quantified and graphed relative to t = 0. The experiment shown is representative of one of three repeats. (C) *cdc55Δ*, but not *swe1Δ*, suppresses the temperature sensitivity of an APC mutant. Eightfold serial dilutions of wild-type (ADR4009), *swe1Δ* (ADR4015), *cdc55Δ* (ADR4738), *cdc16-1* (ADR4979), *cdc16-1 swe1Δ* (ADR4984), and *cdc16-1 cdc55Δ* (ADR5020) cells were spotted onto plates and grown at the indicated temperatures. (D) *cdc55Δ*, but not *swe1Δ*, allows premature anaphase spindle elongation in cells with an impaired APC, but does not bypass APC function. *cdc16-1* (ADR4979), *cdc16-1 swe1*Δ (ADR4984), and *cdc16-1 cdc55*Δ (ADR5020) cells were arrested in G1 with 100 ng/ml α-factor. 1 h before α-factor wash-out, cells were shifted to 34 or 37°C to inactivate Cdc16. Cells were then washed and released from G1 arrest (t = 0) at either 34 or 37°C. Samples for fluorescence microscopy were taken at the indicated time points and the distance between Spc42-eGFP--labeled SPBs was measured in at least 100 cells. Anaphase spindles were defined as spindles \>3 µm in length.](JCB_201212038R_Fig6){#fig6}

If PP2A^Cdc55^ inhibits the APC by dephosphorylation, we wondered if *cdc55Δ* cells may be able to suppress mutations in APC subunits. The temperature-sensitive mutants *cdc16-1* and *cdc23-1* are both partially suppressed by *cdc55Δ* but not by *swe1Δ* ([Fig. 6 C](#fig6){ref-type="fig"}; Fig. S3 D). When *cdc55Δ cdc16-1* cells are grown at a semi-restrictive temperature of 34°C a large fraction of cells proceed into anaphase ([Fig. 6 D](#fig6){ref-type="fig"}), while *cdc16-1* and *swe1Δ cdc16-1* cells remain arrested with short metaphase spindles. However, *cdc55Δ* does not bypass APC function, as *cdc55Δ cdc16-1* cells grown at the fully restrictive temperature of 37°C behave indistinguishably from *swe1Δ cdc16-1* and *cdc16-1* cells. A similar result has been reported in *Drosophila*, where a mutation in Cdc27 (*mks*) is suppressed by a mutation of a PP2A B-subunit (*twins/aar*; [@bib23]).

Blocking APC phosphorylation suppresses checkpoint defects
----------------------------------------------------------

Because *cdc55Δ* cells increase APC phosphorylation, we tested if the morphogenesis checkpoint defect of *cdc55Δ* is suppressed by mutating the known Cdk1 phosphorylation sites on the APC. Combining *apc-12A* with *cdc55Δ* completely rescues the slow degradation of Pds1 and Clb2 seen in *cdc55Δ* cells ([Fig. 7 A](#fig7){ref-type="fig"}). Swe1 and tyrosine phosphorylation on Cdk1 are also stabilized in *cdc55Δ apc-12A.* Consistent with APC substrate stabilization, latA-treated *cdc55Δ apc-12A* cells only slowly reinitiate DNA replication (Fig. S3 E).

![**PP2A^Cdc55^-dependent dephosphorylation of Cdk1 sites on the APC inhibits anaphase onset.** (A and B) Mutation of 12 Cdk1 phosphorylation sites on the APC in morphogenesis checkpoint-activated cells blocks *cdc55*Δ-dependent activation of the APC. *cdc55*Δ (ADR4738), *cdc55*Δ *apc-12A* (ADR4902), and *apc-12A* (ADR4973) cells were grown and treated with latA as in [Fig. 3 A](#fig3){ref-type="fig"} and samples for immunoblotting (A) and fluorescence microscopy (B) were taken at the indicated time points. More than 200 cells were scored for each data point in B. The data shown are from one representative experiment out of two repeats. (C and D) Mutation of 12 Cdk1 phosphorylation sites on the APC in spindle checkpoint-activated cells blocks *cdc55Δ*-dependent activation of the APC and rapid loss of viability. Wild-type (ADR4009), *mad2*Δ (ADR4099), *cdc55*Δ (ADR4738), *cdc55*Δ *apc-12A* (ADR4902), and *apc-12A* (ADR4973) cells were arrested in G1 with 100 ng/ml α-factor, released from G1, 10 µg/ml nocodazole was added at t = 35, and 800 ng/ml α-factor was re-added at t = 65 to arrest cells in the following G1. Samples for immunoblotting (C) and viability assays (D) were taken at the indicated time points. Viability (average ± SEM) was calculated from three independent experiments relative to viability at t = 0.](JCB_201212038R_Fig7){#fig7}

The spindle checkpoint also acts through APC inhibition ([@bib39]; [@bib45]), so we wondered if *cdc55Δ* bypasses both the morphogenesis and spindle checkpoints through increased APC phosphorylation. Similar to the effect of *swe1Δ* on the morphogenesis checkpoint ([Fig. 3 A](#fig3){ref-type="fig"}), *mad2Δ* bypasses the spindle checkpoint and activates APC-dependent proteolysis with normal timing ([Fig. 7 C](#fig7){ref-type="fig"}; [@bib63]). Like the morphogenesis checkpoint and in contrast to *mad2Δ* cells, *cdc55Δ* cells bypass the spindle checkpoint despite slow activation of the APC, and this slow activation is completely blocked in *cdc55Δ apc-12A* cells ([Fig. 7 C](#fig7){ref-type="fig"}). The rapid loss of viability that accompanies *cdc55Δ* checkpoint bypass ([Fig. 7 D](#fig7){ref-type="fig"}, blue line) is also significantly suppressed in *cdc55Δ apc-12A* cells (red line).

Discussion
==========

The morphogenesis checkpoint arrests cells at metaphase
-------------------------------------------------------

We have shown that chronic tyrosine phosphorylation of Cdk1 triggered by the morphogenesis checkpoint arrests cells at metaphase with short metaphase spindles that have made bipolar attachments to sister chromatids ([Fig. 2](#fig2){ref-type="fig"} and [Fig. 8](#fig8){ref-type="fig"}). During this arrest Cdk1--cyclin complexes are inhibited, showing that metaphase can occur during periods of relatively low Cdk1 activity. Additionally, in unperturbed cell cycles *swe1Δ* mutants shorten and *mih1Δ* mutants lengthen metaphase, suggesting that the removal of inhibitory phosphorylation on Cdk1 is an important trigger of anaphase onset in every cell cycle.

![**Cdk1 activates and PP2A^Cdc55^ inhibits anaphase onset.** Our data support a model in which Cdk1 and PP2A^Cdc55^ regulate phosphorylation of the APC and Esp1. In this model, Cdk1 regulates Esp1 directly by phosphorylation, and indirectly through modulation of APC^Cdc20^ activity and Pds1 degradation. Dephosphorylation of tyrosine 19 on Cdk1 by the Mih1 (Cdc25) phosphatase allows normal anaphase onset by activating Cdk1, whereas Swe1 (Wee1) phosphorylation slows anaphase onset by phosphorylating and inhibiting Cdk1. During a morphogenesis checkpoint arrest, Swe1 is inhibited and Mih1 is activated, thereby blocking anaphase. Deletion of *CDC55* allows premature activation of the APC and Esp1, which bypasses the morphogenesis checkpoint arrest despite continued signaling through inhibitory phosphorylation of Cdk1. Premature activation of the APC and Esp1 in *cdc55Δ* mutants could also explain *cdc55Δ* bypass of the spindle and DNA damage checkpoints, which block anaphase by inhibiting Cdc20 activity and Pds1 destruction, respectively ([@bib63]; [@bib109]; [@bib39]; [@bib45]; [@bib88]; [@bib101]).](JCB_201212038_Fig8){#fig8}

The literature on the morphogenesis checkpoint has been equivocal on where the checkpoint arrests the cell cycle. Although some work has pointed to a function in mitosis ([@bib11]; [@bib3]; [@bib94]; [@bib102]; [@bib16]), most have focused on the G2/M transition, presumably because of past work on fission yeast and vertebrate Wee1 and Cdc25 ([@bib54]; [@bib61]; [@bib44]). An additional difficulty has been historical and semantic: the description of many budding yeast mutants that arrest with short mitotic spindles and bipolar attachments, such as APC mutants, have been described as having a G2/M arrest despite the evidence that these cells arrest in metaphase ([@bib33]). Here we define G2 and mitosis in universal terms: G2 is the time before spindle assembly and kinetochore capture by the mitotic spindle, and mitosis begins when spindle poles separate and the spindle assembles.

*swe1Δ* cells initiate mitotic entry 5--10 min earlier than wild-type cells after release from a G1 arrest (Fig. S1 D; [@bib34]; [@bib79]; [@bib71]), suggesting that Swe1 also functions in G2. One report has suggested that the delay in spindle assembly is due to the destabilization of the microtubule motors Cin8 and Kip1 ([@bib19]). Our data and others ([@bib14]) do not agree with this interpretation, as Cin8 and Kip1 levels peak before Cdk1 is dephosphorylated, showing that Cin8 and Kip1 abundance is not regulated by Cdk1 activity (Fig. S1 E). Additionally, our analysis of Cdk1 phosphotyrosine levels through the cell cycle differs dramatically from that published in the above report ([Fig. 1 A](#fig1){ref-type="fig"}). These authors based many of their conclusions about the role of inhibited Cdk1 on the phenotype of a *cdk1-Y19E* mutant. Although the Y19E substitution may mimic tyrosine phosphorylation and decrease Cdk1 activity ([@bib56]), it is likely that this mutation has additional defects as has been shown in the *cdk1-T18V, Y19F* and *cdk1-Y19F* mutants ([@bib83]).

Stepwise activation of Cdk1 triggers anaphase
---------------------------------------------

Numerous studies have suggested that inhibitory phosphorylation regulates Cdk1 activation in a stepwise manner in both vertebrates and yeast ([@bib98]; [@bib76], [@bib77]; [@bib24]; [@bib36]). These studies have primarily focused on how Cdk1 dephosphorylation by Cdc25 allows cells to transition from G2 to mitosis. Other work has suggested a second step in Cdk1 activation during mitosis that regulates anaphase onset ([@bib83]; [@bib58]; [@bib79]). Mutation of two yeast mitotic cyclins, *CLB1* and *CLB2*, arrests cells in metaphase, showing that a low level of Cdk1 activity can drive spindle assembly, but additional activity is needed to trigger anaphase ([@bib79]). Our work suggests that Cdk1 dephosphorylation may cause the increase in Cdk1 activity that triggers anaphase onset, in part by activation of the APC ([Fig. 8](#fig8){ref-type="fig"}). In fission yeast and vertebrates high levels of tyrosine-phosphorylated Cdk1 arrests cells in G2, and mitotic entry requires a large change in Cdk1 activity. Budding yeast may use different Cdk1 activity thresholds, rendering mitotic onset relatively impervious to Swe1-dependent Cdk1 inhibition, and instead use this inhibition to control anaphase onset.

After overexpression of Swe1, residual Cdk1--cyclin activity remains in cells ([Fig. 4 D](#fig4){ref-type="fig"}). Because tyrosine phosphorylation of Cdk1 has been shown to completely inhibit Cdk1 activity ([@bib73]), we believe only a fraction of Cdk1 is targeted by Swe1, and this pool of Cdk1 is equally phosphorylated when the morphogenesis checkpoint is activated, despite far lower levels of Swe1 ([Fig. 4 A](#fig4){ref-type="fig"}). How cells restrict Swe1 activity even when it is overexpressed is unknown, but may reflect limited import of Swe1 into the nucleus where its function is needed to activate the morphogenesis checkpoint ([@bib43]).

If dephosphorylation of Cdk1 is a primary trigger for anaphase onset, why does deletion of *MIH1*, unlike mutants of *cdc25^+^* in fission yeast, have only a mild phenotype ([@bib70]; [@bib87])? Although Mih1 is the only Cdc25 homologue in budding yeast at least one other phosphatase dephosphorylates Cdk1, as Cdk1 is dephosphorylated in *mih1Δ* cells as Clb5 and Pds1 destruction initiates (Fig. S1 B; [@bib72]). PP2A^Cdc55^ has been proposed to be a second Cdk1 phosphatase because *mih1Δ cdc55Δ* cells are inviable ([@bib72]), but this synthetic interaction could be explained instead by PP2A^Cdc55^ regulation of Swe1 ([@bib36]).

Do Wee1 and Cdc25 in other organisms also influence anaphase onset? One study in unperturbed human cells correlated mitotic progression with Cdk1 tyrosine phosphorylation and showed that spindle assembly begins before any appreciable change in Cdk1 tyrosine phosphorylation ([@bib58]). In addition, Cdk1 dephosphorylation is completed just before maximal APC3 (the human Cdc27 homologue) phosphorylation and cyclin B proteolysis. This work suggests that as in yeast ([@bib83]; [@bib79]), vertebrates have a Cdk1 activity threshold that is required to initiate anaphase, and the complete dephosphorylation of Cdk1 during mitosis may assist in achieving this threshold.

The APC is a target of the morphogenesis checkpoint
---------------------------------------------------

Swe1-dependent inhibition of Cdk1 reduces APC activity in vivo and in vitro and this inhibition is accompanied by dephosphorylation of the APC, suggesting the APC is a target of the morphogenesis checkpoint ([Fig. 5](#fig5){ref-type="fig"} and [Fig. 8](#fig8){ref-type="fig"}). To prove that APC phosphorylation is a target of the checkpoint we examined the unusual checkpoint defect of *cdc55Δ* cells, which is characterized by checkpoint bypass despite relatively slow degradation of APC substrates ([Fig. 3 A](#fig3){ref-type="fig"}; [@bib63]; [@bib109]; [@bib16]). Deletion of *CDC55* increases APC phosphorylation in vivo ([Fig. 6 A](#fig6){ref-type="fig"} and [Fig. 8](#fig8){ref-type="fig"}) and purified PP2A^Cdc55^ dephosphorylates the APC in vitro ([Fig. 6 B](#fig6){ref-type="fig"}) suggesting a model that in *cdc55Δ* cells checkpoint inhibition of the APC is countered by increased phosphorylation and activation of the APC. Consistent with this model, mutation of 12 APC phosphorylation sites in *cdc55Δ* cells suppresses premature APC activation during both morphogenesis and spindle checkpoint activation, and prevents rapid lethality after exposure to nocodazole ([Fig. 7](#fig7){ref-type="fig"}). These results are consistent with prior studies that have suggested that PP2A may dephosphorylate and inhibit the APC^Cdc20^ in yeast, insect, and human cells ([@bib23]; [@bib7]; [@bib67]; [@bib108]).

APC inhibition is sufficient but may not be necessary to block anaphase
-----------------------------------------------------------------------

We have also demonstrated that in budding yeast, as in other eukaryotes ([@bib52]; [@bib92]; [@bib48]; [@bib47]), Cdk1--Clb2 can activate the APC^Cdc20^ in vitro, and this activation requires the phosphorylation sites in Cdc16 and Cdc27. This is the first demonstration that defects caused by APC phosphorylation site mutants in vivo correlate with changes in APC activity in vitro, and confirms that these sites contribute to APC--Cdc20 binding ([@bib82]). Similar to mutations in Cdc23 and Cdc27 that weaken activator binding ([@bib60]), decreased phosphorylation of the APC reduces all ubiquitinated species equally (Fig. S4 E), arguing that phosphorylation does not affect APC processivity.

It remains unclear if APC phosphorylation is an essential function of Cdk1, as it has not been shown that mutating APC subunits to prevent APC phosphorylation blocks anaphase. Although past work has suggested that the TPR subunits are the primary phosphorylated subunits of the APC ([@bib82]; [@bib117]; [@bib96]), we have shown that Apc1 also contains Cdk1-dependent phosphorylation ([Fig. 4 A](#fig4){ref-type="fig"}) and there may also exist additional unidentified Cdk1 sites on the APC. Phosphorylation of the APC may be essential in multicellular organisms---a single study has shown that mutating two sites in the *Drosophila cdc27* cannot rescue a lethal P-element insertion into the endogenous *cdc27* ([@bib38]).

One study has shown that rapid and complete inhibition of the analogue-sensitive Cdk1-as1 causes a dramatic inhibition of *CDC20* transcription and drop in protein levels ([@bib55]). Though this is an attractive model for how morphogenesis checkpoint activation delays anaphase onset, it appears that regulation of *CDC20* transcription is not the key target of the morphogenesis checkpoint for two reasons: (1) In contrast to Cdk1-as1 inhibition, Cdc20 is stable during morphogenesis checkpoint activation (Fig. S5 C), and (2) restoring Cdc20 levels after inhibiting Cdk1-as1 does not reverse a block to anaphase onset ([@bib55]). Cdc20 regulation appears to be more complicated in *Xenopus* egg extracts where Cdk1-dependent phosphorylation of Cdc20 inhibits its binding to the APC, and regulated dephosphorylation by PP2A promotes anaphase onset ([@bib48]; [@bib51]).

If Cdk1 regulated anaphase onset solely through the APC^Cdc20^ then deletion of APC substrates should be sufficient to bypass a morphogenesis checkpoint arrest. Cells lacking *PDS1* and *CLB5* (as well as *SGO1*), the two essential APC^Cdc20^ substrates ([@bib91]), retain the ability to block anaphase in response to latA treatment, suggesting that APC inhibition may not be necessary for cell cycle arrest during checkpoint activation (Fig. S3, G and H; [@bib16]). Inhibition of the APC does, however, prevent checkpoint bypass of *swe1Δ* cells (Fig. S3 I), showing APC inhibition is sufficient to block anaphase. These results suggest that inhibition of Cdk1 phosphorylation of a second target acts redundantly to maintain sister chromatid cohesion during morphogenesis checkpoint arrest ([Fig. 8](#fig8){ref-type="fig"}).

Cdk1 and PP2A^Cdc55^ regulate anaphase onset by two mechanisms
--------------------------------------------------------------

Although the *apc-12A* mutations suppress some of the *cdc55Δ* defects, the timing of anaphase onset is similar in *cdc55Δ* and *cdc55Δ apc-12A* cells after latA treatment ([Fig. 7 B](#fig7){ref-type="fig"}). In addition, despite premature anaphase onset in *cdc55Δ cdc16-1* cells grown at 34°C ([Fig. 6 D](#fig6){ref-type="fig"}), there is little difference in the kinetics of APC substrate degradation compared with *swe1Δ cdc16-1* and *cdc16-1* cells (Fig. S3 F). These data argue strongly that anaphase onset can be regulated independently of APC activation, and that PP2A^Cdc55^ regulates a second target downstream of the APC. This conclusion is supported by past work showing that *cdc55Δ* mutants initiate anaphase in cells expressing a stabilized form of Pds1, which normally blocks sister chromatid separation ([@bib101]).

Other reports have shown that PP2A^Cdc55^ inhibits activation of the FEAR pathway and release of Cdc14 from the nucleolus ([@bib110]; [@bib115]). Although premature Cdc14 release might allow derepression of the APC^Cdh1^ and some APC proteolysis, this model doesn't satisfactorily explain how *cdc55Δ* cells prematurely initiate sister chromatid separation in the absence of Pds1 degradation ([Fig. 5, A and B](#fig5){ref-type="fig"}; [Fig. 7 B](#fig7){ref-type="fig"}; [@bib101]; [@bib16]). PP2A^Cdc55^ could function downstream of Pds1 destruction by regulating Separase activity directly, or regulate Cohesin cleavage, and prior data supports both models ([@bib78]; [@bib113]). We favor a model whereby Cdk1 activates and PP2A^Cdc55^ inhibits both the APC and Esp1 ([Fig. 8](#fig8){ref-type="fig"}). This redundancy would reinforce the switch-like onset of anaphase and could assist cells during recovery from checkpoint arrests when the APC may become active more slowly than in an unperturbed mitosis.

Materials and methods
=====================

Strain and plasmid construction
-------------------------------

[Table I](#tbl1){ref-type="table"} lists the strains used in this work. All strains are derivatives of the W303 strain background (W303-1a; see [Table 1](#tbl1){ref-type="table"} for complete genotype). All deletions and replacements were confirmed by immunoblotting, phenotype, or PCR. The sequences of all primers used in this study are available upon request. The bacterial strains TG1 and DH5α were used for amplification of DNA, and Rosetta (EMD Millipore) was used for protein purification.

###### 

Strain list

  Strain    Mating type   Genotype
  --------- ------------- ----------------------------------------------------------------------------------------------------------------
  ADR22     *MAT*α        wild type W303-1a[a](#tblfn1){ref-type="table-fn"}
  ADR477    *MAT**a***    *CDC28-HA-URA3*
  ADR797    *MAT**a***    *leu2::pGAL-SWE1-HA-LEU2 bar1Δ::LEU2 pep4Δ::TRP1*
  ADR806    *MAT**a***    *ura3::pGAL-SIC1-Δ3P-HA-His~6~ bar1Δ::LEU2 pep4Δ::TRP1*
  ADR809    *MAT**a***    *bar1Δ::LEU2 pep4Δ::TRP1*
  ADR877    *MAT**a***    *mih1Δ::LEU2*
  ADR1168   *MAT**a***    *cdc15-2*
  ADR1373   *MAT**a***    *leu2::pGAL-SWE1-HA-LEU2 mih1Δ::LEU2 CDC28-HA-URA3*
  ADR1393   *MAT**a***    *trp1::lacO-256X::TRP1 his3::pCup1-GFP12-lacI12::HIS3 bar1Δ*
  ADR1395   *MAT**a***    *trp1::lacO-256X::TRP1 his3::pCup1-GFP12-lacI12::HIS3 mih1Δ::LEU2 leu2::pGAL-SWE1-HA-LEU2 CDC28-HA-URA3 bar1Δ*
  ADR1435   *MAT**a***    *cdh1Δ::HIS3*
  ADR2260   *MAT*α        *mih1Δ::LEU2*
  ADR2617   *MAT**a***    *PDS1-myc18X-leu2::HIS3 bar1Δ*
  ADR3089   *MAT**a***    *CDC16-TAP-HIS3 bar1Δ*
  ADR3141   *MAT**a***    *swe1Δ::TRP1 mih1Δ::LEU2 cdc20-3*
  ADR3149   *MAT**a***    *mih1Δ::LEU2 cdc20-3*
  ADR3155   *MAT**a***    *swe1Δ::TRP1 cdc20-3*
  ADR3168   *MAT*α        *mih1Δ::LEU2 swe1Δ::TRP1*
  ADR3161   *MAT**a***    *cdc20-3*
  ADR3170   *MAT**a***    *swe1Δ::TRP1*
  ADR3178   *MAT**a***    *mih1Δ::LEU2*
  ADR3738   *MAT**a***    *PDS1-myc18X-leu2::HIS3 mih1Δ::KAN^R^ leu2::pGAL-swe1-N584A-HA-LEU2 bar1Δ*
  ADR3740   *MAT**a***    *PDS1-myc18X-leu2::HIS3 mih1Δ::KAN^R^ leu2::pGAL-SWE1-HA-LEU2 bar1Δ*
  ADR3822   *MAT*α        *cdc16-6A-TAP-KlURA3*
  ADR3858   *MAT**a***    *CDC16-TAP-HIS3 mih1Δ::KAN^R^ leu2::pGAL-SWE1-HA-LEU2 bar1Δ*
  ADR3859   *MAT**a***    *CDC16-TAP-HIS3 mih1Δ::KAN^R^ leu2::pGAL-SWE1-HA-LEU2 bar1Δ*
  ADR3871   *MAT**a***    *PDS1-myc18X-leu2::HIS3 mih1Δ::KAN^R^ leu2::pGAL-SWE1-HA-LEU2 bar1Δ*
  ADR3877   *MAT*α        *CDC16-TAP-HIS3 swe1Δ::TRP1 mih1Δ::LEU2*
  ADR3891   *MAT**a***    *cdc16-6A-TAP-KlURA3 cdc27-5A-KAN^R^*
  ADR3919   *MAT**a***    *PDS1-myc18X-leu2::HIS3 mih1Δ::KAN^R^ mec1Δ::TRP1 sml1Δ::NAT^R^ leu2::pGAL-SWE1-HA-LEU2 bar1Δ*
  ADR3921   *MAT**a***    *PDS1-myc18X-leu2::HIS3 mec1Δ::TRP1 sml1Δ::NAT^R^ bar1Δ*
  ADR3938   *MAT**a***    *PDS1-myc18X-leu2::HIS3 mad2Δ::URA3*
  ADR3940   *MAT**a***    *PDS1-myc18X-leu2::HIS3 mad2Δ::URA3 mih1Δ:KAN^R^ leu2::pGAL-SWE1-HA-LEU2*
  ADR4006   *MAT**a***    *bar1Δ*
  ADR4009   *MAT**a***    *SPC42-eGFP-KAN^R^ bar1Δ*
  ADR4012   *MAT**a***    *mih1Δ::LEU2 SPC42-eGFP-KAN^R^ bar1Δ*
  ADR4015   *MAT**a***    *swe1Δ::TRP1 SPC42-eGFP-KAN^R^ bar1Δ*
  ADR4060   *MAT**a***    *cdc15-2 cdc55Δ::LEU2 CDC16-TAP-HIS3*
  ADR4099   *MAT**a***    *mad2Δ::URA3 SPC42-eGFP-KAN^R^ bar1Δ*
  ADR4169   *MAT**a***    *PDS1-myc18X-leu2::HIS3 SPC42-GFP-HYG^R^ bar1Δ*
  ADR4171   *MAT**a***    *PDS1-myc18X-leu2::HIS3 SPC42-GFP-HYG^R^ mih1Δ::KAN^R^ leu2::pGAL-SWE1-HA-LEU2 bar1Δ*
  ADR4191   *MAT**a***    *KIP1-myc13X-NAT^R^ CIN8-GFP-HYG^R^ bar1*Δ
  ADR4193   *MAT**a***    *PDS1-myc18X-leu2::HIS3 CIN8-GFP-HYG^R^ bar1*Δ
  ADR4197   *MAT**a***    *mih1Δ::LEU2 swe1Δ::TRP1 APC1-TAP-URA3*
  ADR4198   *MAT**a***    *mih1Δ::LEU2 leu2::pGAL-SWE1-HA-LEU2 APC1-TAP-URA3*
  ADR4228   *MAT**a***    *PDS1-myc18X-leu2::HIS3 mih1Δ::KAN^R^ HYG^R^ -cdc28-Y19F leu2::pGAL-SWE1-HA-LEU2 bar1Δ*
  ADR4245   *MAT**a***    *PDS1-myc18X-leu2::HIS3 mih1Δ::KAN^R^ cdc15-2 leu2::pGAL-SWE1-HA-LEU2*
  ADR4252   *MAT**a***    *PDS1-myc18X-leu2::HIS3 cdc15-2*
  ADR4289   *MAT**a***    *mih1Δ::KAN^R^ leu2::pGAL-SWE1-HA-LEU2 CIN8-eGFP-HYG^R^ bar1*Δ
  ADR4313   *MAT**a***    *KAN^R^-cdc28-Y19F SPC42-eGFP-HYG^R^ bar1Δ*
  ADR4647   *MAT**a***    *sgo1Δ::HYG^R^ pds1*Δ*::NAT^R^ pMET-CLB5-KAN^R^ SPC42-eGFP-Sphis5^+^ bar1*Δ
  ADR4738   *MAT**a***    *cdc55*Δ*::HIS3 SPC42-eGFP-KAN^R^ bar1*Δ
  ADR4902   *MAT**a***    *cdc16-6A-TRP1 cdc27-5A-KAN^R^ cdc23-A-HA cdc55*Δ*::his3::LEU2 SPC42-eGFP-HYG^R^ bar1*Δ
  ADR4909   *MAT**a***    *mih1Δ::KAN^R^ swe1Δ::TRP1 HA3X-Cdh1 bar1Δ*
  ADR4910   *MAT**a***    *mih1Δ::KAN^R^ swe1Δ::TRP1 his3::pGAL-SWE1-HIS3 HA3X-CDH1 bar1Δ*
  ADR4973   *MAT**a***    *cdc16-6A-TRP1 cdc27-5A-KAN^R^ cdc23-A-HA SPC42-eGFP-HYG^R^ bar1*Δ
  ADR4979   *MAT**a***    *cdc16-1 SPC42-eGFP-KAN^R^ bar1*Δ
  ADR4984   *MAT**a***    *swe1Δ::TRP1 cdc16-1 SPC42-eGFP-KAN^R^ bar1*Δ
  ADR5020   *MAT**a***    *cdc16-1 cdc55Δ::HIS3 SPC42-eGFP-KAN^R^ bar1Δ*
  ADR5026   *MAT**a***    *NDC80-eGFP-Sphis5^+^ bar1*Δ
  ADR5137   *MAT**a***    *cdc15-2 cdc55Δ::LEU2 swe1Δ::TRP1 CDC16-TAP-HIS3 bar1Δ*
  ADR5297   *MAT**a***    *RTS1-TAP-HIS3 bar1Δ*
  ADR5465   *MAT**a***    *CDC55-TAP-klTRP1 bar1Δ*
  ADR5599   *MAT**a***    *cdc23-1 SPC42-eGFP-KAN^R^ bar1Δ*
  ADR5600   *MAT**a***    *swe1Δ::TRP1 cdc23-1 SPC42-eGFP-KAN^R^ bar1*Δ
  ADR5623   *MAT**a***    *cdc55Δ::HIS3 cdc23-1 SPC42-eGFP-KAN^R^ bar1*Δ

W303-1a is *ura3-1 leu2-3,112 trp1-1 his3-11 ade2-1 can1-100*.

*CDC16-TAP-HIS3* strains were made by crossing TC80 (a gift of Christopher Carroll and David Morgan, UCSF, San Francisco, CA; [@bib12]) to the appropriate strains. The *CDC55-TAP-klTRP1* strain was made using pBS1479 ([@bib80]) and the appropriate oligonucleotides. *cdc15-2*, *cdc20-3*, and *PDS1-myc18X-leu2::HIS3* strains were made by crossing K1993, K8029, and K6445 (gifts of Kim Nasmyth, University of Oxford, Oxford, UK) to the appropriate strains and the *LEU2* converted to *HIS3* with pLH7 ([@bib21]). The plasmids used to make *leu2:*:*pGAL-SWE1-HA-LEU2* and *leu2::pGAL-swe1-N584A-HA-LEU2* are pSwe1-41 (a gift of Bob Booher, Onyx Pharmaceuticals, Richmond, CA; [@bib5]) and pSH14 (a gift of Stacey Harvey and Douglas Kellogg, UCSC, Santa Cruz, CA; [@bib35]), respectively. *HA3X-CDH1* strains were made by crossing A1576 (a gift of Angelika Amon, MIT, Cambridge, MA) to the appropriate strains. *ura3::pGAL-SIC1-Δ3P-HA-HIS~6~* was derived from RJD961 (a gift of Raymond Deshaies and Rati Verma, California Institute of Technology, Pasadena, CA; [@bib105]).

*BAR1* was deleted using pJGsst1 (a gift of Jeremy Thorner, University of California, Berkeley, CA). *his3::pCup1-GFP12-lacI12::HIS3* and *trp1::lacO-256X::TRP1* were made by integrating pSB116 ([@bib4]) and pAFS59 ([@bib99]), respectively. *MIH1* was deleted using pIP33 (a gift of Peter Sorger, Massachusetts Institute of Technology, Cambridge, MA). *swe1Δ::TRP1* strains were made by crossing JM449 (a gift of Jeremy Minshull, DNA2.0, Menlo Park, CA) to the appropriate strains. *cdc55Δ::HIS3* was created using pJM6 ([@bib63]) and *cdc55Δ::his3::LEU2* converted to *LEU2* using pHL3 ([@bib21]). *CDC28-HA-URA3* was made as described previously ([@bib5]). *cdc16-1* and *cdc23-1* are derived from the A364A strains H16C1B1 and H23C1A1 ([@bib33]) and have been backcrossed at least five times to W303-1a.

*CDH1* was deleted using pAR127. An EcoRI--HindIII fragment of the *CDH1* locus was amplified by PCR and cloned into pSK(−) (Agilent Technologies) to create pAR125. An XbaI--SmaI fragment of the *HIS3* gene was then cloned into pAR125 cut with SpeI--XmnI, to create pAR127, which replaces the entire *CDH1* open reading frame with *HIS3*. The EcoRI--NotI fragment of pAR127 was used to transform yeast.

*cdc16-6A-TRP1*, *cdc23-A-HA*, and *cdc27-5A-KAN^R^* alleles were made as described previously ([@bib82]). Alanine-substituted mutants in *CDC16*, *CDC23*, and *CDC27* were made using site-directed mutagenesis ([@bib50]). Mutations were confirmed by the introduction of new restriction enzyme sites and by sequencing (ABI). For *CDC16*, the EcoR1--Xho1 fragment of pWAM10 ([@bib53]) was cloned into KS(−) (Agilent Technologies) to create pAR290. pAR290 was mutagenized to create pAR293, which contains all six serine/threonine-to-alanine substitutions. pAR294 was cut with EcoRI and NotI, and ligated to a EcoRI--PstI PCR fragment that contains the 3′ end of *CDC16*, a PstI--SpeI PCR fragment that contains the *TRP1* gene, and a SpeI--NotI PCR fragment that contains the 3′ untranslated region of the *CDC16* gene. The resultant plasmid, pAR303, was cut with XhoI and NotI, and integrated at the *CDC16* locus. The *TRP1* transformants were screened by PCR for the presence of all mutations. For *CDC23*, the BamHI--NotI fragment of pRS239 ([@bib53]) was cloned into KS(−) to create pAR228. pAR228 was mutagenized to create pAR240, which contains the single serine-to-alanine substitution in *CDC23*. pAR228 was cut with BamHI and NotI, transformed into *cdc23-1* cells, and selected for growth at 37°C. Transformants were screened by Western blot for the HA tag present at the 3′ end of the gene, and by PCR for the presence of the alanine substitution. For *CDC27*, the PstI--NotI fragment of pJL25 ([@bib53]) was cloned into KS(−) to create pAR201. pAR201 was mutagenized to create pAR203, which contains all five serine/threonine-to-alanine substitutions in *CDC27*. pAR203 was cut with NdeI and NotI, and ligated to a NdeI--XbaI PCR fragment that contains the *KAN^R^* gene and a XbaI--NotI PCR fragment containing the 3′ untranslated region of *CDC27*. The resultant plasmid, pAR271, was cut with KpnI and NotI, and integrated at the *CDC27* locus. Transformants were screened by PCR for the presence of all mutants. The *cdc16-6A-TAP-klURA3* allele was made by amplifying a *TAP-klURA3* cassette from pBS1539 ([@bib80]), integrating it into the *cdc16-6A*-*TRP1* strain, and selecting for presence of the TAP tag and *URA3* and loss of *TRP1.*

*CIN8-GFP-HYG^R^*, *KIP1-myc13X-NAT^R^*, and *SGO1-myc13X-HIS3* were created using PCR-targeted recombination using pFA6a-GFP(S65T)-kanMX6 and pFA6a-13Myc-kanMX6 ([@bib59]) and gene-specific primers and the marker was switched by homologous recombination using a *HYG^R^* or *NAT^R^* cassette amplified off pAG32 or pAG25 ([@bib30]). *SPC42-eGFP-KAN^R^*, *SPC42-eGFP-Sphis5^+^*, and *NDC80-eGFP-Sphis5^+^* were created by amplifying eGFP and a marker off pKT127 and pKT128 ([@bib90]), and *SPC42-eGFP-HYG^R^* was made by switching *KAN^R^* to *HYG^R^* using pAG32. *PDS1*, *SGO1*, *MEC1*, *SML1*, and *MIH1* were deleted using cassettes amplified from pAG32, pAG25, pRS404, and directly from the *MATa* yeast deletion array (Thermo Fisher Scientific).

*KAN^R^- pMET3-CLB5* was created by amplifying *KAN^R^- pMET3* cassette from pAR704 with *CLB5* specific primers. pAR704 was made by inserting a PCR-amplified *pMET3* (from −626 to −1) into the BglII and SalI sites of pFA6a-kanMX ([@bib59]). *his3::pGAL-SWE1-HIS3* was created from pAR707. The full-length *SWE1* gene was amplified from genomic DNA and cloned into pAR121 as a Xho1--BamH1 fragment. pAR121 is pRS303 with the *GAL1-10* promoter cloned between Kpn1--Xho1. pAR707 was integrated at the *his3-11* locus after restriction digestion with Nhe1.

*KAN^R^* (or *HYG^R^*)-*CDC28-Y19F* was created from two overlapping PCR fragments: *KAN^R^* or *HYG^R^* (amplified from pFA6a-kanMX6 and pAG32) and the promoter (from −334 to −1) and 5′ region of the *CDC28-Y19F* allele, including the mutation (amplified from pSF38; a gift of Peter Sorger, Harvard Medical School, Boston, MA). These two fragments were used to create a single long cassette that was integrated by homologous recombination. Positive transformations were determined by amplifying the 5′ region of *CDC28* and digesting this fragment with NdeI, which was inserted near the Y19F substitution in pSF38. Additionally, positive *KAN^R^*-*CDC28-Y19F* strains have no detectable Cdk1-Y19 phosphorylation as determined by immunoblotting using an α-Cdk1-P-Tyr antibody.

Physiology
----------

Unless noted in the figure legend, cells were grown in yeast extract peptone media + 2% dextrose (YEPD) at 25 or 30°C. Cell cycle arrests were performed with 10 µg/ml nocodazole (Sigma-Aldrich), 25--100 ng/ml α-factor (Biosynthesis), and 2.5--5 µM latA (Sigma-Aldrich or Tocris Bioscience), or at 35°C for 2.5--3 h. LatA efficacy varied between batches and companies so the amount necessary to induce a fully Swe1-dependent arrest was determined empirically.

To fix cells for microscopy, ∼2.0 × 10^6^ cells were harvested and fixed with 4% paraformaldehyde in PBS, pH 7.5, for 15 min, washed in 100 mM KPO~4~/1.2 M sorbitol, pH 7.5, sonicated, and resuspended in KPO~4~/sorbitol. Samples were imaged directly using a microscope (Ti; Nikon) with a Plan Apo 60× 1.4 NA objective (Nikon) and FITC filter set (Chroma Technology Corp.) at room temperature with a camera (CoolSnap HQ2; Photometrics). A minimum of 200 cells was visually scored per time point.

Live microscopy
---------------

Live imaging pads were made by adding 25% gelatin (wt/vol) to SC media at 56°C, pipetting 50 µl between two microscope slides, and allowing it to cool. 1--2 µl of cultures were pipetted onto live imaging pads, covered by a coverslip and sealed with VALAP (1:1:1 Vaseline/lanolin/petroleum jelly). Strains were imaged at 25°C for 2 h using bright-field and a FITC filter set (Chroma Technology Corp.) on either a fluorescence microscope (model DMI6000B; Leica) with a Plan Apo 63× 1.40 NA objective (Leica) and a camera (Orca AG; Hamamatsu Photonics) or on a microscope (Ti; Nikon) with a Plan Apo 60× 1.40 NA objective (Nikon) and a camera (CoolSnap HQ2; Photometrics). 17 Z-slices, spaced every 0.5 µm were imaged at each time point. Fluorescence excitation was attenuated using neutral density filters and 100--200-ms exposure times were used for both GFP and bright-field acquisition. Measurements were made using Volocity (PerkinElmer) or NIS-Elements software (Nikon). Look-up tables were manually adjusted linearly. Example images were prepared using ImageJ software (National Institutes of Health).

FACS analysis
-------------

For each time point 1.0 × 10^7^ cells were harvested and resuspended in 70% ethanol. Samples were rotated overnight at 4°C, pelleted, and treated with 0.25 mg/ml RNase (Thermo Fisher Scientific) for 1 h at 50°C. After RNase treatment, cells were treated with 0.25 mg/ml proteinase K (Thermo Fisher Scientific) for 1 h at 60°C, stained with Sytox Green (Molecular Probes), and incubated for 30 min at room temperature. Samples were sonicated before analysis and analyzed using either an FC500 or CyAn ADP (Beckman Coulter) flow cytometer using a 488-nm laser.

Western blots and immunoprecipitation
-------------------------------------

These methods have been described previously ([@bib82]; [@bib83]). Immunoprecipitations were performed in APC lysis buffer (50 mM Hepes-KOH, pH 7.8, 700 mM NaCl, 150 mM NaF, 150 mM Na-β-glycerophosphate pH 8.3, 1 mM EDTA, 1 mM EGTA, 5% glycerol, 0.25% NP-40, 1 mM DTT, 1 mM PMSF, 1 mM Na~3~VO~4~, 1 mM benzamidine, and leupeptin, bestatin, pepstatin A, and chymostatin all at 1 mM).

The following antibodies were used for Western blots and immunoprecipitations: The use of 9E10 ascites (Covance), α-Clb2, α-Clb3, 12CA5 ascites (Covance), and α-Cdc27 have been described previously ([@bib82]; [@bib83]). Rabbit polyclonal α-Sgo1, α-Pds1, α-Clb5, α-Cdk1, α-Swe1, and α-Cdc20 were used at 1:1,000; α-Orc6 at 1:2,000; and α-GFP at 1:4,000 in TBS-T with 4% fat-free milk powder, 5% glycerol, and 0.02% NaN~3~. α-P-cdc2 (Tyr15-4539; Cell Signaling Technology) was used at a dilution of 1:1,000 in TBS-T, 4% BSA, and 0.02% NaN~3~. An autoclaved solution of 5% milk was used to make the 4% milk dilution buffer to increase the longevity of the antibody solution. Membranes were preblocked with TBS-T with 4% fat-free milk powder before incubation with all primary antibodies.

α-Clb5, α-Pds1, and α-Sgo1 antibodies were generated as follows. Coding sequences for the truncated proteins Clb5~2-137~, Pds1~178-373~, and Sgo1~129-326~ were amplified using PCR and cloned into pGEX6P-1 (Promega) as BamH1--EcoR1 fragments to create pAR627, pAR624, and pAR717, respectively. 1 mg of each GST fusion protein was injected into rabbits every 4 wk for 8--16 wk (uOttawa Animal Facility, Ottawa, Ontario, Canada). Rabbit serum was harvested, clarified by centrifugation, and loaded on Affigel-10 (Bio-Rad Laboratories) columns coupled to purified malE-Clb5, malE-Pds1, or malE-Sgo1, respectively. malE-fusion proteins were expressed from the plasmids pAR651, pAR652, and pAR724, which contain the same fragments listed above cloned as BamH1--Sal1 fragments into pMAL-c2 (New England Biolabs, Inc.). Antibody was eluted from Affigel columns with either 100 mM triethylamine, pH 11.5, or 100 mM glycine, pH 2.3. The triethylamine and glycine elutions were neutralized, dialyzed in PBS + 50% glycerol, and stored at −80°C.

Plasmids GST-Swe1~2-312~ (in pGEX-4T3, pAR622), malE-Swe1~2-819~ (in pMAL-c2, pAR623), and His~6~-Cdk1~2-298~ (pAR727; gifts of Vu Thai and Doug Kellogg, UCSC, Santa Cruz, Santa Cruz, CA; [@bib94]) were used to produce GST-Swe1 and His~6~-Cdk1 protein for injection into rabbits as described above. α-Swe1 antibodies were purified on Affigel-10 (Bio-Rad Laboratories) columns coupled to purified malE-Swe1. α-Cdk1 antibodies were purified using an Affigel-15 (Bio-Rad Laboratories) column coupled to purified His~6~-Cdk1, which is insoluble, so the coupling was done in the presence of 0.3% SDS.

α-GFP serum (a gift of Aaron Straight \[Stanford University, Stanford, CA\] and Andrew Murray \[Harvard University, Cambridge, MA\]) was generated by immunizing rabbits with bacterially expressed His~6~-GFP (pAFS97), and purified as above using an Affigel-10 (Bio-Rad Laboratories) column coupled to purified His~6~-GFP.

α-Cdc20 antibody was generated as described previously ([@bib8]). Rabbit sera was purified as above using an Affigel-15 (Bio-Rad Laboratories) column coupled to purified His~6~-Cdc20~470-610~, which was expressed from a BamH1--Not1 fragment cloned into pHIS-parallel2 to create pAR784. His~6~-Cdc20~470-610~ is insoluble, so the coupling was done in the presence of 0.3% SDS.

α-Orc6 antibody was a kind gift of Joachim Li (UCSF, San Francisco, CA).

Ubiquitination assay
--------------------

Purification of the APC using a C-terminal TAP tag on Cdc16 and ubiquitination assays were performed as described previously ([@bib9]; [@bib60]). Harvested cells were lysed in APC lysis buffer (see above). The clarified lysate was incubated with IgG-coupled magnetic beads (Invitrogen) for 1 h at 4°C. ^35^S-methionine labeled substrates Pds1-ZZ, Pds1-dbkb-ZZ and Clb5-HA-ZZ, Clb5-dbΔ-HA-ZZ, and unlabeled activators ZZ-Cdc20 and ZZ-Cdh1 (gifts of Maria Enquist, Scott Foster, and David Morgan, UCSF, San Francisco, CA) were made in vitro (TnT T7 Quick Coupled Transcription/Translation System; Promega), and purified with IgG-coupled magnetic beads. Proteins were cleaved from beads for 30 min at 25°C with TEV protease. His~6~-Uba1 was purified from yeast, and His~6~-Ubc1 and His~6~-Ubc4 were purified from bacteria as described previously ([@bib10]; [@bib81]). Ubiquitination (and phosphorylation, below) was quantified using a phosphorimager (Molecular Dynamics) or a Typhoon Trio phosphorimager and ImageQuant software (GE Healthcare).

In vivo labeling of the APC
---------------------------

*CDC16-TAP* cells were arrested in mitosis by spindle checkpoint activation with nocodazole or in anaphase by temperature shift. Once the cells were arrested at the indicated stage of the cell cycle, 10 × 10^7^ cells were harvested by centrifugation and labeled in 2 ml phosphate-free synthetic medium containing 0.5--1 mCi ^32^PO~4~ (GE Healthcare or PerkinElmer) as described previously ([@bib82]). Uptake of label was monitored by scintillation counting (TriCarb 2910TR; PerkinElmer) of the cells and media, and exceeds 98%.

Purification of Cdk1--Clb2 and PP2A^Cdc55^ complexes
----------------------------------------------------

pRS326 containing *pGAL-CLB-TAP*, pAR546, was created by in vivo recombination in yeast by cotransforming the *CLB2* gene with overlapping homology to a BamH1--HindIII-digested pRS-AB1234 (pGAL-TAP) plasmid (a gift of Christopher Carroll and David O. Morgan, UCSF, San Francisco, CA) and Clb2-TAP was overexpressed by growth in galactose. Cdc55--CBP complexes were purified from asynchronously growing *CDC55-TAP* (ADR 5465) cells.

Harvested cells were lysed in APC lysis buffer and purified as described previously ([@bib84]). The activity of purified Cdk1--Clb2-CBP complexes was assayed with histone H1 kinase assays (see below).

Kinase and phosphatase assays
-----------------------------

Phosphorylation of histone H1 and the APC has been described previously ([@bib82]). For histone H1 kinase assays, Clb-associated complexes were purified with 1--2 µl of α-Clb2, α-Clb3, or α-Clb5 antibodies and protein A magnetic beads (Invitrogen), and incubated with 2.5 µg histone H1 (EMD Millipore). To phosphorylate the APC, the APC was purified as described, bound to IgG-coupled beads, and treated with purified Cdk1--Clb2 complexes. Kinase reactions for both were performed with cold ATP (1 mM for cold reactions and 0.01 mM for hot reactions), and 1 µCi γ-\[^32^P\]ATP. APC phosphorylated with unlabeled ATP was washed, cleaved, and tested in the ubiquitination assay. Dephosphorylation of the APC was measured by incubating in vitro--phosphorylated APC still bound to beads with TAP-purified PP2A^Cdc55^ complexes or lambda phosphatase (New England Biolabs, Inc.). Okadaic acid (LC Laboratories) was used at 2 µM.

Online supplemental material
----------------------------

Fig. S1 shows alterations in mitotic progression in *swe1Δ* and *mih1Δ* cells. Fig. S2 shows analysis of anaphase kinetics in wild-type, *swe1Δ*, and *mih1Δ* cells. Fig. S3 provides additional controls that the APC is a target of the morphogenesis checkpoint. Fig. S4 provides additional data that overexpression of Swe1 arrests cells in mitosis and does not depend on the spindle or DNA damage checkpoints. Fig. S5 provides additional controls that Swe1 regulates APC^Cdc20^, as well as silver-stained gels of the reagents used in [Figs. 4](#fig4){ref-type="fig"} and [6](#fig6){ref-type="fig"}, and additional quantification. Online supplemental material is available at <http://www.jcb.org/cgi/content/full/jcb.201212038/DC1>.
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